Ascendis Pharma A/S will hold its annual general meeting on March 23, 2026 in Copenhagen, Denmark. Shareholders will vote on the election of the chair of the meeting; a report on the company’s activities during the past year; approval of the audited annual report and discharge of the board of directors and management from liability; the proposed application of results, including carrying forward a consolidated loss of EUR 228 million; election of board members, including the re-election of all current board members and the election of Jean-Jacques Bienaimé as a new non-executive board member; election of Deloitte as auditor for statutory financial and sustainability reporting; and an authorization for the board to purchase treasury shares or corresponding American Depositary Shares up to a total nominal value of DKK 1,000,000.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Ascendis Pharma A/S published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission (Ref. ID: 0001193125-26-063954), on February 23, 2026, and is solely responsible for the information contained therein.